SYNkinase: Your first choice for small molecule inhibitors


Epigenetics is the study of regulatory mechanisms that influence gene expression independently of the DNA sequence. These mechanisms include modification of the DNA by methylation on specific cytosine residues and of specific chromatin proteins such as histones by methylation and acetylation. Histone acetylation and deacetylation play important roles in the modulation of chromatin structure and the regulation of gene transcription.

Patterns of Epigenetic modifications can be inherited and also altered in disease states such as cancer. For example the expression of tumor suppressor genes can be silenced by promoter methylation.

Increasingly epigenetic modifications are being targeted by specific therapies. An example is the use of histone deacetylase inhibitors (HDACi) in cancer treatment. Histone deacetylase inhibitors are a new class small molecule drugs that inhibit the proliferation of cancer cells by inducing cell cycle arrest, differentiation or cell death.

The bromodomain and extra terminal domain (BET) family of proteins, including BRD2, BRD3, and BRD4, control the assembly of histone acetylation-dependent chromatin complexes and thereby play a key role in many cellular processes.

Synkinase provide a wide range of inhibitors that target Epigenetics modification for research use that have been cited in numerous peer-review publications.

They are available in many formats and product sizes.